CKD

OPKO Health, Inc., has submitted the a New Drug Application (NDA) for oral Rayaldee to the U.S. Food and Drug Administration (FDA). The Rayaldree would be Indicated for the treatment of secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency. View the full release here.